doi: Īutosomal dominant hyper-IgE syndrome (AD-HIES) is typically caused by dominant-negative (DN) STAT3 mutations. Uhlig, Filomeen Haerynck, Jean-Laurent Casanova, Anne Puel Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome. Freeman, Émilie Catherinot, Claire Fieschi, Talal A. Milner, Bodo Grimbacher, Louis-Jean Couderc, Manish J. Esther, Sule Haskologlu, Figen Dogu, Peter Ciznar, David Boutboul, Marie Ouachée-Chardin, Jean Amourette, Marie-Noëlle Lebras, Clément Gauvain, Colas Tcherakian, Aydan Ikinciogullari, Rudi Beyaert, Laurent Abel, Joshua D. Vogel, Undiagnosed Diseases Network, Charles R. Lambrecht, Véronique Avettand-Fenoel, Tiphanie P. Kohn, Marieke De Bruyne, Klaus Schmitz-Abe, Louis-Marie Charbonnier, Sevgi Keles, Justine Nammour, Natasha Vladikine, Majistor Raj Luxman Maglorius Renkilaraj, Yoann Seeleuthner, Mélanie Migaud, Jérémie Rosain, Mohamed Jeljeli, Bertrand Boisson, Eva Van Braeckel, Jill A. Ma, Marie Materna, Arian Laurence, Jens Staal, Dominik Aschenbrenner, Lisa Roels, Lisa Worley, Kathleen Claes, Lisa Gartner, Lisa A. Haerynck reported, "Centre for Primary Immune deficiency is recognized as a Jeffrey Modell Foundation diagnostic and research center and supported by the Jeffrey Modell Foundation the University Hospital Ghent Spearhead Initiative for Immunology Research (until 7/2019) the Grand Challenges Program of VIB (this VIB Program received support from the Flemish Government under the Management Agreement 2017-2021 VR 2016 2312 Doc.1521/4) Simon Tavernier is a postdoctoral fellow at PID research lab with the Fund for Scientific Research Flanders (FWO, 12W9119N) I am funded by a university research grant (BOF-University Ghent)." No other disclosures were reported. Uhlig reported grants from Celgene during the conduct of the study and grants from UCB and Eli Lilly outside the submitted work. Catherinot reported financial support for travel and registration expenses related to international medical meetings (LVL Medical, CSL Behring). Couderc reported non-financial support from Astra Zeneca, personal fees from Boehringer Ingelheim, personal fees from Novartis, and grants from LVL outside the submitted work. Milner reported a patent to use STAT3 inhibition to prevent anaphylaxis pending. Rosenfeld reported personal fees from Baylor Genetics Laboratories outside the submitted work. Chen reported grants from Bristol-Myers Squibb during the conduct of the study.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |